Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.
Loeb S, Keith SW, Cheng HH, Leader AE, Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown LH, Pieczonka CM, Gomella LG, Kelly WK, Lallas CD, Handley N, Mille PJ, Mark JR, Brown GA, Chopra S, McClellan A, Wise DR, Hollifield L, Giri VN. Loeb S, et al. Among authors: pieczonka cm. JCO Precis Oncol. 2024 Mar;8:e2300552. doi: 10.1200/PO.23.00552. JCO Precis Oncol. 2024. PMID: 38452310 Free PMC article. Clinical Trial.
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.
Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, Venugopal B, Woo HH, Ramirez-Backhaus M, Supiot S, Lantz A, Ganguli A, Ivanova J, Kral P, Huang SP, Saad F, Shore ND. Freedland SJ, et al. Among authors: pieczonka cm. NEJM Evid. 2023 Dec;2(12):EVIDoa2300251. doi: 10.1056/EVIDoa2300251. Epub 2023 Oct 22. NEJM Evid. 2023. PMID: 38320501 Clinical Trial.
Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
Van Neste L, Henao R, Wojno KJ, Signes J, DeHart J, Busta A, Marriott E, Willing M, Argentini A, Hurley PM, Korman H, Hafron J, Putzi M, Pieczonka CM, Karsh LI, Morris DS, Kassis AI, Kantoff PW. Van Neste L, et al. Among authors: pieczonka cm. J Urol. 2024 Mar;211(3):415-425. doi: 10.1097/JU.0000000000003824. Epub 2023 Dec 26. J Urol. 2024. PMID: 38147400
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN. Shen J, et al. Among authors: pieczonka cm. Br J Cancer. 2024 Jan;130(1):73-81. doi: 10.1038/s41416-023-02492-8. Epub 2023 Nov 11. Br J Cancer. 2024. PMID: 37951974 Free PMC article.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND. Freedland SJ, et al. Among authors: pieczonka cm. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. N Engl J Med. 2023. PMID: 37851874 Clinical Trial.
Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer.
Shore ND, Polikarpov DM, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, Beebe-Dimmer JL, Ruterbusch JJ, Levin RA, Wissmueller S, Le TH, Gillatt DA, Chan DW, Deng N, Siddireddy JS, Lu Y, Campbell DH, Walsh BJ. Shore ND, et al. Among authors: pieczonka cm. Urol Oncol. 2023 Nov;41(11):454.e9-454.e16. doi: 10.1016/j.urolonc.2023.08.005. Epub 2023 Sep 19. Urol Oncol. 2023. PMID: 37734979
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.
Antonarakis ES, Subudhi SK, Pieczonka CM, Karsh LI, Quinn DI, Hafron JM, Wilfehrt HM, Harmon M, Sheikh NA, Shore ND, Petrylak DP. Antonarakis ES, et al. Among authors: pieczonka cm. Clin Cancer Res. 2023 Jul 5;29(13):2426-2434. doi: 10.1158/1078-0432.CCR-22-3832. Clin Cancer Res. 2023. PMID: 37058234 Free PMC article.
A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial.
Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, Beebe-Dimmer JL, Ruterbusch JJ, Le TH, Levin RA, Wissmueller S, Prah P, Borotkanics R, Paivanas TA, van Breda A, Campbell DH, Walsh BJ. Shore ND, et al. Among authors: pieczonka cm. Urol Oncol. 2020 Aug;38(8):683.e1-683.e10. doi: 10.1016/j.urolonc.2020.03.011. Epub 2020 Apr 30. Urol Oncol. 2020. PMID: 32360170
Development and evaluation of the MiCheck test for aggressive prostate cancer.
Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, Beebe-Dimmer JL, Ruterbusch JJ, Levin RA, Wissmueller S, Le TH, Gillatt D, Chan DW, Campbell DH, Walsh BJ. Shore ND, et al. Among authors: pieczonka cm. Urol Oncol. 2020 Aug;38(8):683.e11-683.e18. doi: 10.1016/j.urolonc.2020.03.010. Epub 2020 Apr 16. Urol Oncol. 2020. PMID: 32305266
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
Higano CS, Armstrong AJ, Sartor O, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR. Higano CS, et al. Among authors: pieczonka cm. Cancer. 2020 Jun 15;126(12):2935-2937. doi: 10.1002/cncr.32785. Epub 2020 Mar 10. Cancer. 2020. PMID: 32154908 Free PMC article. No abstract available.
19 results